Wednesday, February 11, 2026

RPE Modeling May Advance AMD Research

Researchers from the National Institutes of Health use AI to develop a 3D atlas of healthy and diseased RPE cell states.

Wednesday, February 11, 2026

ACET Launches Technician Training Program to Address Workforce Shortage

The virtual course provides participants with critical knowledge in anatomy, disease, testing, optics, and patient safety.

Wednesday, February 11, 2026

RETeval Electroretinography Device Gets New Partner

Ametek has announced its acquisition of LKC Technologies.

Wednesday, February 11, 2026

4DMT Completes Enrollment in Phase 3 Gene Therapy Trial for Wet AMD

The phase 3 4FRONT-1 study compares 4D-150, an investigational gene therapy, against aflibercept 2 mg in treatment-naïve patients.

Tuesday, February 10, 2026

BVI Launches Finevision HP IOL in the United States

Initial cases signal the start of a phased US rollout of the presbyopia-correcting IOL platform, BVI reports.

Friday, February 6, 2026

ZipBio, MeiraGTx Enter License Agreement to Advance Gene Therapy for GA

Under the agreement, MeiraGTx will receive exclusive rights to ZipBio's first-in-class therapies for geographic atrophy, targeting the complement pathway.

Tuesday, February 3, 2026

Aeye Health Expands Epic Integration for AI Eye Screening

This enhanced integration allows primary care providers, endocrinologists, and diabetes centers to perform on-the-spot diabetic eye exams without physician interpretation

Monday, February 2, 2026

AI-Powered Patient Education Platform Introduced

The platform is managed through a user-friendly clinic dashboard, and is customizable to suit clinic branding and workflows. 

Thursday, January 29, 2026

FDA Approves Yuvezzi Combination Eye Drop for Presbyopia

Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, is the first dual-agent eye drop for the treatment of presbyopia in adults.

Wednesday, January 28, 2026

iDose TR Gains FDA Approval for Retreatment

Updated labeling permits repeat implantation in patients meeting corneal safety criteria.

Tuesday, January 27, 2026

Prevent Blindness Declares February AMD and Low Vision Month

Prevent Blindness is providing free educational resources on AMD and low vision including patient and expert videos, webpages, fact sheets, and more. 

Tuesday, January 27, 2026

New Data Demonstrate Qlosi is Pupil Selective With Ciliary Muscle Movement

In an imaging study from the Bascom Palmer Eye Institute, Qlosi's low-concentration formulation with 0.4% pilocarpine significantly reduced pupil diameter while demonstrating ciliary muscle movement the same as balanced salt solution control. 

Monday, January 26, 2026

Novaliq Announces FDA Clearance of Uveitis Program

The clearance allows initiation of the phase 2 EYETAC clinical trial in patients with noninfectious anterior uveitis.

Monday, January 26, 2026

BioTissue Completes Sale of Non-Ocular Surgical, Wound Care Business to BioStem

Under the agreement, BioStem will acquire exclusive rights to the Neox and Clarix product lines. 

Monday, January 26, 2026

FDA Grants Orphan Drug Designation to Cell Therapy for Retinitis Pigmentosa

OpCT-001 is an investigational induced pluripotent stem cell–derived cell therapy being tested in a phase 1/2a clinical study for the treatment of primary photoreceptor diseases, including retinitis pigmentosa and cone-rod dystrophy. 

Friday, January 23, 2026

SpyGlass Randomizes First Patients in Phase 3 Trials for BIM-IOL System

A pair of registrational trials will compare the company’s bimatoprost-eluting lens to a standard lens plus drops.

Tuesday, January 20, 2026

Focus Vitamins Launches Preservative-Free Drops for Dry Eye

The preservative-free eye drops are available in single-dose vials. 

Tuesday, January 20, 2026

Japan Advances Regulatory Review of MCO-010

Sakigake and Orphan Drug designations granted; FDA has conditionally approved the Mogenry brand name.

Tuesday, January 20, 2026

Ocugen Reports Positive Phase 2 Data From OCU410 Gene Therapy for GA

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs control

Tuesday, January 20, 2026

Generic Equivalent of Extra-Strength Pataday Once Daily Relief Now Available

Dr. Reddy’s olopatadine hydrochloride ophthalmic solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander, the company said.

Friday, January 16, 2026

TheraTears Expands Dry Eye Portfolio With Eyelid Cleansing Wipes, Drops

TheraTears announced 2 new additions to its portfolio launching nationwide in February 2026: TheraTears Eyelid Cleansing Wipes and TheraTears Dry & Tired Preservative Free Lubricant Eye Drops.

Wednesday, January 14, 2026

FDA Clears Rayner's Sophi Phaco System

The company said that surgeons and clinical teams can benefit from faster setup, quicker patient turnover, and greater mobility.

Tuesday, January 13, 2026

RevitalVision Demonstrates Efficacy, Safety in Infantile Nystagmus

Positive clinical data shows improvement in visual function in patients with infantile nystagmus

Tuesday, January 13, 2026

Topcon, RemoniHealth Partner to Advance Remote Monitoring and Care Continuity

The strategic partnership expands Topcon's home monitoring and connected-care vision by combining its imaging, AI analytics, and interoperable platforms with RemoniHealth’s remote-monitoring technology.

Tuesday, January 13, 2026

Conexiant Announces 30th Anniversary of Ophthalmology Management

For 3 decades, OM has delivered authoritative coverage of clinical advancements, innovations in surgical technique, regulatory and reimbursement changes, and best practices for efficiency and leadership.

Thursday, January 8, 2026

Ollin Biosciences Reports Positive Results for VEGF/Ang2 Bispecific Antibody

The next-generation VEGF/Ang2 bispecific antibody demonstrates rapid retinal drying and vision gains in patients with diabetic macular edema.

Thursday, January 8, 2026

Complement's Gene Therapy for GA Receives FDA Fast-Track Designation

Complement Therapeutics’s CTx001, an investigational gene therapy that targets complement pathways in geographic atrophy, will be evaluated in a phase 1/2 trial in 2026.

Tuesday, January 6, 2026

FDA Clears IND for GenEditBio’s GEB-101 in TGFBI Corneal Dystrophy

The phase 1/2 CLARITY trial will collect initial data on the safety, tolerability, and efficacy of GEB-101 in corneal dystrophy patients with TGFBI mutation.

Tuesday, January 6, 2026

FDA Grants Oculis' Privosegtor Breakthrough Drug Designation

The designation is supported by results from the phase 2 ACUITY trial, in which Privosegtor was evaluated in patients with acute optic neuritis.

Friday, January 2, 2026

New International Myopia Guidance Urges Early, Personalized Care

The Digest reflects a global expert consensus on the definitions, risk factors, prevention, and management of myopia in children and young adults. 

Friday, January 2, 2026

FDA Issues CRL for Outlook's Resubmitted ONS-5010 BLA

The FDA indicated that it cannot approve the application in its present form for the treatment of wet age-related macular degeneration.

Friday, January 2, 2026

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

Friday, January 2, 2026

Prevent Blindness Takes Part in National Glaucoma Awareness Month With New Webinar 

As part of National Glaucoma Awareness Month in January, Prevent Blindness announced the availability of free educational resources on glaucoma that eyecare professionals can share with their patients.